Skip to main content
. 2021 Mar 1;11:4856. doi: 10.1038/s41598-021-84190-0

Figure 2.

Figure 2

Establishment of an IPM and evaluation of its predictive ability in TCGA AML patients with intermediate and adverse-cytogenetic risk. (a) Risk score distribution and the corresponding survival and gene expression data; (b) Time-dependent ROC curve of the IPM; (c) Comparison between overall survival in the IPM-HR and IPM-LR groups.